NIK Antibody (A-12): sc-8417

NIK Antibody (A-12) is a mouse monoclonal IgG2b kappa light chain antibody designed to target the NFκB Inducing Kinase (NIK), also known as MAP3K14, across human, mouse, and rat species. NIK monoclonal antibody (A-12) specifically recognizes an epitope within amino acids 700-9473 at the C-terminus of the NIK protein, ensuring precise detection in various applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). NIK is a crucial serine/threonine kinase involved in the non-canonical NFκB signaling pathway, where NIK plays a significant role in the activation and processing of NFκB transcription factors. These transcription factors are essential for regulating immune responses, inflammation, and cell survival, making NIK a key player in maintaining immune homeostasis. By interacting with and acting as a co-stimulator for IkB kinase α (IKKα), NIK phosphorylates IkB, leading to its degradation and the subsequent activation of NFκB. Dysregulation of NIK has been implicated in various autoimmune diseases and cancers, highlighting NIK′s importance in disease pathology. NIK (A-12) antibody is available in both unconjugated form and multiple conjugated variants, including agarose, phycoerythrin (PE), fluorescein isothiocyanate (FITC), and several Alexa Fluor® conjugates, providing researchers with versatile options for diverse experimental needs. The broad species reactivity and reliable performance of NIK monoclonal antibody (A-12) make NIK an invaluable tool for investigating the intricate mechanisms of NFκB signaling pathways and their implications in various biological contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

NIK Antibody (A-12) References:

1. Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets.  |  Paul, A., et al. 2018. Cells. 7: PMID: 30347849
2. Targeting NF-κB-Inducing Kinase (NIK) in Immunity, Inflammation, and Cancer.  |  Pflug, KM. and Sitcheran, R. 2020. Int J Mol Sci. 21: PMID: 33187137
3. Pharmacological inhibition of NF-κB-inducing kinase (NIK) with small molecules for the treatment of human diseases.  |  Cheng, J., et al. 2021. RSC Med Chem. 12: 552-565. PMID: 34046627
4. Biliary NIK promotes ductular reaction and liver injury and fibrosis in mice.  |  Zhang, Z., et al. 2022. Nat Commun. 13: 5111. PMID: 36042192
5. EDA2R-NIK signalling promotes muscle atrophy linked to cancer cachexia.  |  Bilgic, SN., et al. 2023. Nature. 617: 827-834. PMID: 37165186
6. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40.  |  Rothe, M., et al. 1995. Science. 269: 1424-7. PMID: 7544915
7. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.  |  Hsu, H., et al. 1996. Cell. 84: 299-308. PMID: 8565075
8. TRAF6 is a signal transducer for interleukin-1.  |  Cao, Z., et al. 1996. Nature. 383: 443-6. PMID: 8837778
9. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1.  |  Malinin, NL., et al. 1997. Nature. 385: 540-4. PMID: 9020361
10. Identification and characterization of an IkappaB kinase.  |  Régnier, CH., et al. 1997. Cell. 90: 373-83. PMID: 9244310
11. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB.  |  DiDonato, JA., et al. 1997. Nature. 388: 548-54. PMID: 9252186
12. Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2.  |  Song, HY., et al. 1997. Proc Natl Acad Sci U S A. 94: 9792-6. PMID: 9275204

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-NIK Antibody (A-12) has 32 citations in a variety of scientific publications.

Primary antibodies like Anti-NIK Antibody (A-12) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

NIK Antibody (A-12) Specifications

Alternate Product Name: NIK

Product Clone Name: A-12

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 700-9473

Epitope Target: NIK

Epitope Species: human

Product Reactivity/Detection: NIK

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 32 citations in various scientific publications

Available Conjugates/Forms for NIK Antibody (A-12): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, PE: Phycoerythrin